PeptideLabs Logo
PeptideLabs
质量文档记录
Back to all 64 profiles
Community/research information only未获 FDA/EMA 批准WADA

Community protocol · BPC-157

BPC-157: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: BPC 157 · Body protection compound 157

Sources checked: 27 August 2026

重要安全与责任声明

本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

BPC-157

在胃肠组织和创伤修复方面开展了临床前研究；临床获益与安全性尚未证实。

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

复配与 U-100 换算

复配计算器

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

复配计算器

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Synthetic 15-amino-acid gastric peptide fragment

BPC-157 is classified as “Synthetic 15-amino-acid gastric peptide fragment”. 在胃肠组织和创伤修复方面开展了临床前研究；临床获益与安全性尚未证实。 This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

胃保护片段

研究人员研究源自胃保护蛋白的片段如何影响模型中胃黏膜愈合和组织修复。测量指标包括动物模型中的溃疡大小和愈合速度。

02

细胞迁移肽

这项研究考察某肽如何影响细胞向损伤部位的迁移,类似于工人们赶往施工现场。在实验室模型中测量细胞迁移的速度和程度。

03

组织修复模型

研究人员在细胞或动物中使用受控的伤口或损伤模型,研究组织受损后愈合的速度和完整程度。测量指标通常包括伤口大小随时间的变化以及新组织形成的标志物,类似于每天拍照记录伤口愈合的速度。

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

伤口愈合轶事

人们报告在使用某些肽后感觉伤口或肌腱问题愈合更快,通常没有对照组或客观测量。这类个人经历并不能证明实际的疗效或安全性。

肠道健康轶事

人们报告在使用胃保护或免疫调节肽后主观感受到的消化改善,通常没有客观诊断依据。这类自我观察无法证明对肠道的确切效果。

恢复与损伤论坛

人们比较在使用不同修复肽时运动损伤后的个人恢复时间,通常基于主观疼痛量表。这类个体经历受许多其他因素影响,并不能证明疗效。

Adverse effects and risk boundaries

  • 许多所谓修复肽缺乏对照人体研究。未知全身效应、免疫反应、出血或血管影响，以及注射相关感染和污染仍是核心风险。
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • 妊娠、癌症、活动性感染、凝血障碍、计划手术及相关免疫疾病需要特别严格的专业评估或避免使用。
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • 未获批修复肽没有经过验证的监测方案。根据具体问题，临床表现、炎症征象、血常规、肝肾功能及凝血可能相关。
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

临床前

证据主要来自临床前研究;人体疗效尚未得到证实。

Published evidence

现有数据主要来自动物或细胞模型;缺乏可靠的人体有效性和安全性数据。

BPC-157源自一种胃保护蛋白,这使其有别于TB-500等胸腺素β4相关片段。

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

未获 FDA/EMA 批准

没有 FDA 或 EMA 批准的药品；有效性与安全性尚未确立。

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile